Literature DB >> 24628093

BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis.

André R Brunoni1, Chris Baeken, Rodrigo Machado-Vieira, Wagner F Gattaz, Marie-Anne Vanderhasselt.   

Abstract

OBJECTIVES: To evaluate whether electroconvulsive therapy (ECT), a very effective non-pharmacological treatment for mood disorders, induces neurotrophic effects, indexed by the measurement of peripheral brain-derived neurotrophic factor (BDNF) levels.
METHODS: Systematic review and meta-analysis of clinical trials published in PubMed/Medline from the first date available to October 2013. We included studies measuring pre- and post-BDNF blood levels under ECT in patients with mood disorders in the acute depressive episode.
RESULTS: Eleven studies (n = 221 subjects) were eligible. These studies enrolled subjects with unipolar, bipolar and psychotic depression and varied regarding electrode placement (unipolar vs. bipolar) and previous use of pharmacotherapy. Nonetheless, BDNF significantly increased after ECT (Hedges' g pooled, random-effects model of 0.354; 95% CI = 0.162-0.546). The results were robust according to sensitivity analysis and Begg's funnel plot did not suggest publication bias. Meta-regression results did not show association of the outcome with any clinical and demographic variable, including depression improvement.
CONCLUSIONS: Our meta-analysis indicates that, similar to pharmacological interventions, peripheral BDNF increases after ECT treatment. The lack of correlation between BDNF increasing and depression improvement suggests that ECT induces neurotrophic effects regardless of clinical response in depression.

Entities:  

Keywords:  brain-derived neurotrophic factor; electroconvulsive therapy; meta-analysis; mood disorders; systematic review

Mesh:

Substances:

Year:  2014        PMID: 24628093     DOI: 10.3109/15622975.2014.892633

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  29 in total

Review 1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.

Authors:  Roumen V Milev; Peter Giacobbe; Sidney H Kennedy; Daniel M Blumberger; Zafiris J Daskalakis; Jonathan Downar; Mandana Modirrousta; Simon Patry; Fidel Vila-Rodriguez; Raymond W Lam; Glenda M MacQueen; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

2.  Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients.

Authors:  Jan Malte Bumb; Suna Su Aksay; Christoph Janke; Laura Kranaster; Olga Geisel; Peter Gass; Rainer Hellweg; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-18       Impact factor: 5.270

3.  BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in depressed patients receiving electroconvulsive therapy.

Authors:  Alexandra Kleimann; Alexandra Kotsiari; Wolfgang Sperling; Michael Gröschl; Annemarie Heberlein; Kai G Kahl; Thomas Hillemacher; Stefan Bleich; Johannes Kornhuber; Helge Frieling
Journal:  J Neural Transm (Vienna)       Date:  2014-11-12       Impact factor: 3.575

4.  A longitudinal study of neurotrophic, oxidative, and inflammatory markers in first-onset depression in midlife women.

Authors:  Matheus A Pasquali; Bernard L Harlow; Claudio N Soares; Michael W Otto; Lee S Cohen; Luciano Minuzzi; Daniel P Gelain; Jose Claudio F Moreira; Benicio N Frey
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-26       Impact factor: 5.270

5.  The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder.

Authors:  Meysam Amidfar; Gislaine Zilli Réus; Airam Barbosa de Moura; João Quevedo; Yong-Ku Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Unfolding the Role of BDNF as a Biomarker for Treatment of Depression.

Authors:  Tarapati Rana; Tapan Behl; Aayush Sehgal; Pranay Srivastava; Simona Bungau
Journal:  J Mol Neurosci       Date:  2020-11-23       Impact factor: 3.444

7.  Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis.

Authors:  André R Brunoni; Rodrigo Machado-Vieira; Carlos A Zarate; Erica L M Vieira; Leandro Valiengo; Isabela M Benseñor; Paulo A Lotufo; Wagner F Gattaz; Antonio L Teixeira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-08-27       Impact factor: 5.067

8.  The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study.

Authors:  Maj Vinberg; Kamilla Miskowiak; Pernille Hoejman; Maria Pedersen; Lars Vedel Kessing
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Motor Cortex Excitability and BDNF Levels in Chronic Musculoskeletal Pain According to Structural Pathology.

Authors:  Wolnei Caumo; Alícia Deitos; Sandra Carvalho; Jorge Leite; Fabiana Carvalho; Jairo Alberto Dussán-Sarria; Maria da Graça Lopes Tarragó; Andressa Souza; Iraci Lucena da Silva Torres; Felipe Fregni
Journal:  Front Hum Neurosci       Date:  2016-07-15       Impact factor: 3.169

Review 10.  Brain-Derived Neurotrophic Factor and Antidepressive Effect of Electroconvulsive Therapy: Systematic Review and Meta-Analyses of the Preclinical and Clinical Literature.

Authors:  M Polyakova; M L Schroeter; B M Elzinga; S Holiga; P Schoenknecht; E R de Kloet; M L Molendijk
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.